

NUFORMIX LIMITED
REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2017

Company Number: 06407331

NUFORMIX LIMITED
REPORT AND FINANCIAL ACTIVITIES
FOR THE YEAR ENDED 31 MARCH 2017

CONTENTS	Page
Directors' report	2
Independent auditors' report	3
Income statement and statement of comprehensive income	5
Statement of total recognised gains and losses	6
Statement of changes in equity	6
Statement of financial position	7
Statement of cash flows	8
Notes to the financial statements	9 - 16

NUFORMIX LIMITED

COMPANY INFORMATION

FOR THE YEAR ENDED 31 MARCH 2017

Directors

Dr D J Gooding
Dr D J Tapolczay
Dr A P Chorlton
Dr J M Holland
Dr T M Cavell-Taylor
Mr Gergely Darvas

Company Secretary

Mr K Siderman-Wolter

Registered Office

The Wilton Centre
Wilton
Redcar
Teesside
TS10 4RF

Company number

06407331

Auditors

haysmacintyre
26 Red Lion Square
London
WC1R 4AG

NUFORMIX LIMITED

DIRECTORS' REPORT

FOR THE YEAR ENDED 31 MARCH 2017

The Directors present their annual report on the affairs of the Company, together with the financial statements for the year ended 31 March 2017.

RESULTS AND DIVIDENDS

The loss for the year, after tax, amounted to £286,913 (2016: £176,257 profit). The Directors do not propose a dividend.

DIRECTORS

The Directors of the Company during the period and subsequently, together with their interests in the equity of the Company are set out below:

	Number of ordinary shares
Joanne Holland	125
David Tapolczay	150
Daniel Gooding	125
Alan Chorlton	140
Dr T M Cavell-Taylor	-
Mr Gergely Darvas	-
Mr Kirk Siderman-Wolter	-

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial period. Under that law the directors have elected to prepare the financial statements in accordance with International Reporting Standards ("IFRS") as adopted by the European Union ("EU") and to prepare the Company financial statements in accordance with IFRS as adopted by the EU. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs and profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether they have been prepared in accordance with IFRSs adopted by the EU;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In the case of each person who was a director at the time this report was approved:

- so far as that director is aware there is no relevant audit information of which the Company's auditor is unaware and
- that director has taken all steps that the director ought to have taken as a director to make himself aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

ON BEHALF OF THE BOARD

Dr D J Gooding
Director

September 2017

INDEPENDENT AUDITORS' REPORT
TO THE MEMBERS OF NUFORMIX LIMITED
FOR THE YEAR ENDED 31 MARCH 2017

We have audited the financial statements of Nuformix Limited for the period ended 31 March 2017 which comprise the Income Statement and Statement of Comprehensive Income, the Statement of Changes in Equity, the Statement of Financial Position, the Statement of Cash flows, and the related notes. The financial reporting framework that has been applied in their preparation of the Company financial statements is applicable law and International Financial Reporting Standards (IFRSs) as adopted by the European Union.

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company members, as a body, for our audit work, for this report, or for the opinion we have formed.

Respective responsibilities of directors and auditors

As explained more fully in the Directors' Responsibilities Statement set out on page 2, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

A description of the scope of an audit of financial statements is provided on the Financial Reporting Council's website at www.frc.org.uk/auditscopeukprivate.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the Company's affairs as at 31 March 2017 and of the its loss for the period the ended,
- have been properly prepared in accordance with IFRS as adopted by the European Union, and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit, the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with those financial statements and such reports have been prepared in accordance with applicable legal requirements.

In the light of our knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Directors' Report.

Emphasis of matter

In forming our opinion on the financial statements, which is not modified, we have considered the adequacy of the disclosure made in note 2 to the financial statements concerning the Group's ability to continue as a going concern having reviewed working capital projections. The position indicates the existence of material uncertainty which may cast doubt about the Group's ability to continue as a going concern due to its reliance on future fundraising. The financial statements do not include any adjustments that would result if the company was unable to continue as a going concern.

INDEPENDENT AUDITORS' REPORT (continued)

TO THE MEMBERS OF NUFORMIX LIMITED

FOR THE YEAR ENDED 31 MARCH 2017

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.
- the directors were not entitled to take advantage of the small companies' exemption from the requirement to prepare a Strategic report.

Ian Cliffe
Senior Statutory Auditor
for and on behalf of haysmacintyre
Statutory Auditors
September 2017

26 Red Lion Square
London
WC1R 4AG

NUFORMIX LIMITED

INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 MARCH 2017

	Note	12 months ended 31 March 2017 £	8 months ended 31 March 2016 £
Turnover		-	405,000
Cost of sales		(86,187)	(47,898)
Gross (loss)/profit		<u>(86,187)</u>	<u>357,102</u>
Administrative expenses	6	(302,574)	(218,393)
Other operating income		35,172	35,868
Operating (loss)/profit		<u>(353,589)</u>	<u>174,577</u>
Interest receivable and similar income		-	7
Interest payable and similar charges		(1,764)	(1,210)
(Loss)/profit on ordinary activities before taxation		<u>(355,353)</u>	<u>173,374</u>
Tax on (loss)/profit on ordinary activities		68,440	2,883
(Loss)/profit for the financial year		<u>(286,913)</u>	<u>176,257</u>
Other comprehensive income		-	-
Total comprehensive (expense)/income for the year		<u><u>(286,913)</u></u>	<u><u>176,257</u></u>

All amounts relate to continuing activities.

The accompanying accounting policies and notes are an integral part of these financial statements.

NUFORMIX LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2017

	Share capital £	Share Premium £	Retained Earnings £	Total Equity £
Brought forward at 1 April 2016	100	509,965	(444,664)	65,401
Loss for the year and total comprehensive loss for the year	-	-	(286,913)	(286,913)
Balance at 31 March 2017	<u>100</u>	<u>509,965</u>	<u>(731,577)</u>	<u>(221,512)</u>

STATEMENT OF CHANGES IN EQUITY

FOR THE PERIOD ENDED 31 MARCH 2016

	Share capital £	Share Premium £	Retained Earnings £	Total Equity £
Brought forward at 1 August 2015	100	509,965	(620,921)	(110,856)
Profit for the period and total comprehensive profit for the period	-	-	176,257	176,257
Balance at 31 March 2016	<u>100</u>	<u>509,965</u>	<u>(444,664)</u>	<u>65,401</u>

The accompanying accounting policies and notes are an integral part of these financial statements.

NUFORMIX LIMITED**STATEMENT OF FINANCIAL POSITION****FOR THE PERIOD ENDED 31 MARCH 2017****Company number: 06407331**

	Note	31 March 2017 £	31 March 2016 £
NON-CURRENT ASSETS			
Intangible fixed assets	10	234,333	175,209
Tangible fixed assets	11	1,733	2,634
		<u>236,066</u>	<u>177,843</u>
CURRENT ASSETS			
Trade receivables	12	84,177	218,507
Cash and cash equivalents	13	4,446	1,568
		<u>88,623</u>	<u>220,075</u>
CURRENT LIABILITIES			
Trade and other payables	14	(546,201)	(332,517)
NET (LIABILITIES)/ASSETS		<u>(221,512)</u>	<u>65,401</u>
EQUITY			
Share capital	15	100	100
Share Premium	15	509,965	509,965
Retained earnings		(731,577)	(444,664)
TOTAL EQUITY		<u>(221,512)</u>	<u>65,401</u>

These financial statements were approved by the Board of Directors on September 2017 and were signed on its behalf by:

Dr D J Gooding
Director

The accompanying accounting policies and notes are an integral part of these financial statements.

NUFORMIX LIMITED

STATEMENT OF CASH FLOWS

FOR THE PERIOD ENDED 31 MARCH 2017

	Note	31 March 2017 £	8 months ended 31 March 2016 £
CASH FLOWS FROM OPERATING ACTIVITIES			
(Loss)/profit before taxation		(355,353)	173,374
Amortisation		33,379	16,086
Depreciation		1,651	1,402
Interest paid		1,765	-
Cash (outflow)/inflow from operations before changes in working capital		(318,558)	190,862
Decrease/(increase) in trade and other receivables		204,726	(149,317)
Increase/(decrease) in trade and other payables		151,888	(27,030)
Cash inflow from operations		38,056	14,515
Income taxes (paid)/received		(1,956)	2,883
Cash inflow from operational activities		36,100	17,398
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of tangible fixed assets		(750)	(1,523)
Purchase of intangible fixed assets		(92,503)	(44,259)
Net cash used in investing activities		(93,253)	(45,782)
CASH FLOWS FROM FINANCING ACTIVITIES			
Loans from directors and third parties		61,796	(32,308)
Interest paid		(1,765)	-
Net cash used in financing activities		60,031	(32,308)
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS			
		2,878	(60,692)
Cash and cash equivalents brought forward		1,568	62,260
CASH AND CASH EQUIVALENTS CARRIED FORWARD	13	4,446	1,568

The accompanying accounting policies and notes are an integral part of these financial statements.

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2017

1. GENERAL INFORMATION

Nuformix Limited is a private limited company incorporated in the United Kingdom. The Company's principal activities are described in the Directors' Report.

2. ACCOUNTING POLICIES

The financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

The financial statements are presented in pounds sterling (£) which is the functional currency of the company.

An overview of standards, amendments and interpretations to IFRSs issued but not yet effective, and which have not been adopted early by the Company are presented below under 'Statement of Compliance'.

Going Concern

The directors have prepared cash flow forecasts through to 31 May 2019 which assumes no significant investment activity is undertaken unless sufficient funding is in place. The expenses of the Company's continuing operations are minimal and the cash flow forecasts demonstrate that the Company is able to meet these liabilities as they fall due. On this basis, the Directors have a reasonable expectation that the Company has adequate resources to continue operating for the foreseeable future. For this reason they continue to adopt the going concern basis in preparing the Company's financial statements.

Critical Accounting Estimates and Judgements

The preparation of financial statement in conformity with IFRS requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. These estimates and assumptions are based upon management's knowledge and experience of the amounts, events or actions. Actual results may differ from such estimates.

Statement of compliance

The financial statements comply with IFRS as adopted by the European Union. At the date of authorisation of these financial statements the following Standards and Interpretations affecting the Company, which have not been applied in these financial statements, were in issue, but not yet effective. The company does not plan to adopt these standards early.

- Amendments to IFRS 2 Share Based Payment (effective for accounting periods beginning on or after 1 January 2018)
- Amendments to IFRS 12 Disclosure of Interests in Other Entities (effective for accounting periods beginning on or after 1 January 2017)
- IFRS 15 Clarification of Revenue from Contracts with Customers (effective for accounting periods beginning on or after 1 January 2018)
- IFRS 16 Leases (effective for accounting periods beginning on or after 1 January 2019)
- Amendments to IAS 7 Statement of Cash Flows (effective for accounting periods beginning on or after 1 January 2017)
- Amendments to IAS 12 Income Taxes (effective for accounting periods beginning on or after 1 January 2017)

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 MARCH 2017

2. ACCOUNTING POLICIES (continued)

Revenue recognition

Revenue comprises the fair value of the franchise income, net of value added tax, rebates and discounts. Revenue is recognised when the Company has a right to that income, the transfer of risks to the customer has taken place and that income can be reliably measured.

Taxation

Current taxation is the taxation currently payable on taxable profit for the period.

Deferred income taxes are calculated using the liability method on temporary differences. Deferred tax is generally provided on the difference between the carrying amounts of assets and liabilities and their tax bases. However, deferred tax is not provided on the initial recognition of an asset or liability unless the related transaction is a business combination or affects tax or accounting profit. Temporary differences include those associated with shares in subsidiaries and joint ventures and are only not recognised if the Company controls the reversal of the difference and it is not expected for the foreseeable future. In addition, tax losses available to be carried forward as well as other income tax credits to the Company are assessed for recognition as deferred tax assets.

Deferred tax liabilities are provided in full, with no discounting. Deferred tax assets are recognised to the extent that it is probable that the underlying deductible temporary differences will be able to be offset against future taxable income. Current and deferred tax assets and liabilities are calculated at tax rates that are expected to apply to their respective period of realisation, provided they are enacted or substantively enacted at the statement of financial position date. Changes in deferred tax assets or liabilities are recognised as a component of tax expense in the income statements, except where they relate to items that are charged or credited to equity in which case the related deferred tax is also charged or credited directly to equity.

Financial assets

The Company's financial assets comprise intangible and tangible fixed assets, trade and other receivables and cash and cash equivalents.

Intangible fixed assets

Intangible fixed assets are stated at fair value less amortisation. They are amortised to the statement of comprehensive income over its estimated economic life. Amortisation is on a 10% straight line basis.

Property, plant and equipment

Property, plant and equipment are stated at cost less depreciation. Depreciation is calculated to write down the cost of all tangible fixed assets by equal monthly instalments over their estimated useful lives at the following rates-

Computer and office equipment – 33.33% straight line

Lab equipment - 25% straight line

Trade and other receivables

Trade and other receivables are recognised and carried at original invoice value less an allowance for any uncollectible amounts. An estimate for doubtful debts is made when collection of the full amount is no longer probable. Bad debts are written off when identified.

Cash and Cash equivalents

Cash and cash equivalents comprise cash on hand and demand deposits, together with other short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE PERIOD ENDED 31 MARCH 2017

2. ACCOUNTING POLICIES (continued)

Financial liabilities

The Company's financial liabilities comprise trade payables. Financial liabilities are obligations to pay cash or other financial assets and are recognised when the Company becomes a party to the contractual provisions of the instruments.

Trade payables

Trade payables are initially measured at fair value and are subsequently measured at amortised cost, using the effective interest rate method.

Equity

Equity comprises the following:

- "Share capital" represents the nominal value of equity shares.
- "Share Premium" represents the amount paid for equity shares over the nominal value.
- "Retained losses" represents retained losses.

3. SEGMENTAL INFORMATION

There is one continuing class of business, being the research and experimental development on biotechnology.

Given that there is only one continuing class of business, operating within the UK no further segmental information has been provided.

4. TURNOVER

Turnover is attributable to the principle activities of the company. All operations are located in the United Kingdom.

5. OTHER OPERATING INCOME

Other operating income relates to government grants receivable in the period.

6. OPERATING PROFIT/(LOSS)	12 months ended 31 March 2017 £	8 months ended 31 March 2016 £
Operating lease rentals – plant and machinery	49	16,680
Depreciation	1,651	1,402
Amortisation	33,379	16,086
Foreign currency losses	19,598	3,151
	<u> </u>	<u> </u>
	<u> </u>	<u> </u>
7. AUDITOR'S REMUNERATION	12 months ended 31 March 2017 £	8 months ended 31 March 2016 £

Fees payable to the Company's auditors for the audit of the Company's

annual accounts	6,000	5,000
-----------------	-------	-------

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE PERIOD ENDED 31 MARCH 2017

8.	DIRECTORS' REMUNERATION	12 months ended 31 March 2017 £	8 months ended 31 March 2016 £
-----------	--------------------------------	--	---

The directors' remuneration for the period was as follows:

Remuneration	147,296	104,086
--------------	---------	---------

9.	TAXATION	12 months ended 31 March 2017 £	8 months ended 31 March 2016 £
-----------	-----------------	--	---

Corporation tax charge /(credit)	(68,440)	(2,883)
----------------------------------	----------	---------

The tax on the Company's profit/(loss) before tax differs from the theoretical amount that would arise using the weighted average rate applicable to the profit/(losses) as follows:

	31 March 2017 £	31 March 2016 £
Factors affecting the tax charge		
Profit/(loss) before tax	(355,354)	173,374
Profit/(loss) before tax multiplied by rate of corporation tax in the UK of 20% (2016: 21%)	(71,071)	34,675
Expenses not deductible for tax purposes	1,026	806
Additional deduction for R&D	(30,267)	(28,765)
Deferred tax not recognised	31,872	(9,599)
Total tax	(68,440)	£(2,883)

No deferred tax asset has been recognised as Directors cannot be certain that future profits will be sufficient for this asset to be realised. As at 31 March 2017 the Company has tax losses carried forward of approximately £nil (2016: £451,999).

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE PERIOD ENDED 31 MARCH 2017

10. INTANGIBLE FIXED ASSETS	Patent £
Cost	
At 1 April 2016	241,287
Additions	92,503
	<hr/>
At 31 March 2017	333,790
	<hr/>
Amortisation	
At 1 April 2016	66,078
Charge for the period	33,379
	<hr/>
At 31 March 2017	99,457
	<hr/>
Net Book Value	
At 31 March 2017	234,333
	<hr/> <hr/>
At 31 March 2016	175,209
	<hr/> <hr/>

11. PROPERTY, PLANT AND EQUIPMENT	Lab Equipment £	Computer Equipment £	Total £
Cost			
At 1 April 2016	9,923	12,358	22,281
Additions	-	750	750
Disposals	(2,355)	(250)	(2,605)
	<hr/>	<hr/>	<hr/>
At 31 March 2017	7,568	12,858	20,426
	<hr/>	<hr/>	<hr/>
Depreciation			
At 1 April 2016	8,333	11,314	19,647
Charge for the period	744	907	1,651
Eliminated on Disposal	(2,355)	(250)	(2,605)
	<hr/>	<hr/>	<hr/>
At 31 March 2017	6,722	11,971	18,693
	<hr/>	<hr/>	<hr/>
Net Book Value			
At 31 March 2017	846	887	1,733
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
At 31 March 2016	1,590	1,044	2,634
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE PERIOD ENDED 31 MARCH 2017

12. TRADE AND OTHER RECEIVABLES	31 March 2017	31 March 2016
	£	£
Trade receivables	-	147,147
Other debtors	84,177	71,360
	<u>84,177</u>	<u>218,507</u>

The fair value of trade and other receivables is considered by the Directors not to be materially different to carrying amounts.

13. CASH AND CASH EQUIVALENTS	31 March 2017	31 March 2016
	£	£
Cash and cash equivalents	4,446	1,568
	<u>4,446</u>	<u>1,568</u>

The Directors consider that the carrying amount of cash and cash equivalent represents their fair value.

14. TRADE AND OTHER PAYABLES	31 March 2017	31 March 2016
	£	£
Trade payables	269,900	110,787
Other taxes and social security	39,429	64,446
Other creditors	236,872	157,284
	<u>546,201</u>	<u>332,517</u>

The fair value of trade and other payables is considered by the Directors not to be materially different to carrying amounts.

15. ISSUED SHARE CAPITAL	Number of Shares	Nominal Value	Share premium
Issued and fully paid	No.	£	£
At 31 March 2017:			
Ordinary shares	1,000	100	509,965
	<u>1,000</u>	<u>100</u>	<u>509,965</u>

16. FINANCIAL INSTRUMENTS

CAPITAL RISK MANAGEMENT

The Company's objectives when managing capital are:

- to safeguard the Company's ability to continue as a going concern, so that it continues to provide returns and benefits for shareholders;
- to support the Company's growth; and
- to provide capital for the purpose of strengthening the Company's risk management capability.

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE PERIOD ENDED 31 MARCH 2017

CAPITAL RISK MANAGEMENT (continued)

The Company actively and regularly reviews and manages its capital structure to ensure an optimal capital structure and equity holder returns, taking into consideration the future capital requirements of the Company and capital efficiency, prevailing and projected profitability, projected operating cash flows, projected capital expenditures and projected strategic investment opportunities. Management regards total equity as capital and reserves, for capital management purposes.

CREDIT RISK

The main credit risk relates to liquid funds held at banks. The credit risk in respect of these bank balances is limited because the counterparties are banks with high credit ratings assigned by international credit rating agencies.

LIQUIDITY RISK

The Company seeks to manage financial risk, to ensure sufficient liquidity is available to meet foreseeable needs.

An analysis of trade and other payables is given in note 14.

CATEGORIES OF FINANCIAL INSTRUMENTS

The IAS 39 categories of financial asset included in the statement of financial position and the headings in which they are included are as follows:

	31 March 2017	31 March 2016
	£	£
Financial assets:		
Intangible fixed assets	234,333	175,209
Tangible fixed assets	1,733	2,634
Trade and other receivables	84,177	218,507
Cash and bank balances	4,446	1,568
Financial liabilities at amortised cost:		
Trade and other payables	546,200	332,517
Other creditors	-	-
	<u> </u>	<u> </u>

17. RELATED PARTY TRANSACTIONS

During the period the company made the following related party transactions:

Dr D Gooding (Director)

Included in creditors due in less than one year is an interest free loan from Dr D Gooding. At the balance sheet date the amount owed to Dr D Gooding was £43,734 (2016 - £8,143).

Dr J Holland (Director)

Included in creditors due in less than one year is an interest free loan from Dr J Holland. At the balance sheet date the amount owed to Dr J Holland was £24,979 (2016 - £2,723).

Dr D Tapolczay (Director)

Included in creditors due in less than one year is a £50,000 loan which was not repaid by 31 December 2016 and so interest became due, but has been waived. Further interest free loans of £43,700 have also been made. At the balance sheet date the amount owed to Dr D Tapolczay was £93,700 (2016 - £93,700).

NUFORMIX LIMITED

NOTES TO THE FINANCIAL STATEMENTS (continued)

FOR THE PERIOD ENDED 31 MARCH 2017

17. RELATED PARTY TRANSACTIONS (continued)

Dr A Chorlton (Director)

Included in creditors due in less than one year is a £10,000 loan which was not repaid by 31 December 2016 so interest became due, but has been waived. At the balance sheet date the amount owed to Dr A Chorlton was £10,000 (2016 - £10,000).

18. POST BALANCE SHEET EVENTS

On 21 April 2017, Nuformix Limited entered into an interest free loan of £125,000 from Levrett Plc. The loan is repayable on demand to Levrett Plc following the completion of Nuformix Limited's acquisition by Levrett Plc. In the event that the acquisition does not complete the loan is not repayable other than in certain prescribed situations relating to the appointment of administrators or receivers or the winding up of Nuformix Limited when, in such cases, the loan becomes repayable immediately.

19. ULTIMATE CONTROLLING PARTY

At the balance sheet date, the Company was controlled by the directors who own 54% of the called up share capital.